ArticleClinical and translational gastroenterology2018
Baclofen and gastroesophageal reflux disease: seeing the forest through the trees.
Article in Clinical and translational gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials.Frontiers in medicine · 2023Pooled it
- GABACurrent topics in behavioral neurosciences · 2022Review
- Arecae pericarpium extract induces porcine lower-esophageal-sphincter contraction via muscarinic receptors.BMC complementary medicine and therapies · 2021Article
- Baclofen therapeutics, toxicity, and withdrawal: A narrative review.SAGE open medicine · 2021Review
- Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2020Review
- Non-acid Reflux: When It Matters and Approach to Management.Current gastroenterology reports · 2020Review
- New Developments in the Diagnosis and Management of Gastroesophageal Reflux.Current treatment options in gastroenterology · 2020Review
- The Medical Management of Gastroesophageal Reflux Disease: A Narrative Review.Journal of primary care & community healthReview
Corrections and comments
- Comment on
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baclofen has been shown to decrease reflux events and increase lower esophageal sphincter pressure, yet has never established a clear role in the treatment of gastroesophageal reflux disease (GERD). Lei and colleagues have shown in a recent elegant study that baclofen reduces the frequency and initiation of secondary peristalsis and heightens esophageal sensitivity to capsaicin-mediated stimulation. These findings may help explain both the benefit of baclofen in conditions such as rumination and supragastric belching, as well as the apparent lack of benefit of baclofen and other GABA
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.